Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7MH25 | — |
Engeirx-B adult dose administration in a 18-year-old patient; Overdose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 18-year-old female patient who received HBV (Engerix B adult) (batch number 7MH25, expiry date 07-DEC-2025) for prophylaxis. On an unknown date, the patient received Engerix B adult. On an unknown date, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Engeirx-B adult dose administration in a 18-year-old patient) and overdose (Verbatim: Overdose). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-AUG-2025 A nurse wanted to get safety information and want to know if there was any concern that they should inform the family. After one of her patients aged 18 received an adult dose of Engerix-B, which led to adult product administered to child and overdose. The vaccine administration facility was the same as primary reporter.